Mounjaro vs Ozempic in Sri Lanka

Why This Comparison Comes Up So Often

Two medicines dominate the questions we get about weight in Colombo: tirzepatide, known by the brand name Mounjaro, and semaglutide, known by brand names including Ozempic. People usually arrive having read a great deal online and having decided which one they want, which is exactly the wrong way round. These are prescription-only medicines. Whether either is suitable, and which one, is a clinical decision made after an assessment.

This guide exists to give you the background properly: the biology, the published evidence with the trials named, an honest comparison, what drives the cost, who should not take them, and what supervision actually involves. It is general information, not medical advice, and it is not an offer to supply any medicine.

What GLP-1 Actually Is

GLP-1, or glucagon-like peptide-1, is a hormone your gut releases after you eat. It has several jobs. It tells the pancreas to release insulin when blood sugar is rising, it suppresses glucagon (the hormone that pushes sugar out of storage), it slows the rate at which the stomach empties, and it signals fullness to the appetite centres in the brain.

Natural GLP-1 breaks down within minutes. The medicines in this class are engineered versions of that hormone that resist breakdown and last around a week in the body, which is why they are given as a once-weekly injection. Semaglutide is a GLP-1 receptor agonist: it does one thing, and it does it for a week at a time.

The practical effect that patients describe is less about willpower and more about noise. Many people say the constant background thinking about food quietens down. Meals feel satisfying earlier, and the urge to eat again arrives later.

What Adding GIP Changes

GIP, or glucose-dependent insulinotropic polypeptide, is a second gut hormone released after eating. It works on insulin release alongside GLP-1, and it also acts on fat tissue and on appetite pathways in the brain, although the full picture is still being researched.

Tirzepatide is a single molecule that activates both the GIP and the GLP-1 receptors, which is why it is described as a dual agonist rather than a GLP-1 agonist. The theory is that engaging two complementary pathways produces a larger effect on appetite and on how the body handles energy than engaging one. The trial results are consistent with that theory, though the two medicines have never been compared head to head across every relevant population, so the comparison has to be read carefully.

What the Published Trials Showed

Any clinic that quotes you a guaranteed number is telling you something it cannot know. What can honestly be reported is what named trials measured, in defined populations, under structured conditions. Individual results vary widely, and trial conditions are not everyday life in Colombo.

Two things are worth drawing out of that table. First, the tirzepatide figures are larger, but they come from a different trial, in a different population, over a different length of time, so they are not a like-for-like scorecard. Second, semaglutide currently carries the larger body of long-term cardiovascular outcome evidence, which matters a great deal for some patients and very little for others.

How the Two Compare

Neither column is automatically better. A patient with established cardiovascular disease, a patient with retinopathy, a patient who has already failed one of the two, a patient on an oral contraceptive and a patient with a history of severe reflux will each be steered differently. That is the point of an assessment.

Side Effects and the Rare but Serious Risks

The common side effects of both medicines are gastrointestinal, and they are common enough that you should plan for them rather than be surprised by them. Nausea, vomiting, diarrhoea, constipation, indigestion and abdominal discomfort are typical, usually worst in the days after starting or after a dose increase, and usually settling as the body adjusts. Slow, small, lower-fat meals help considerably.

The less common but serious risks are the reason supervision matters:

• Pancreatitis, which presents as severe or persistent abdominal pain, often spreading to the back and with vomiting. This needs urgent medical attention.
• Gallbladder problems and gallstones, which become more likely when weight falls quickly.
• Dehydration from vomiting or diarrhoea, which can be severe enough to affect kidney function.
• Low blood sugar when either medicine is combined with insulin or a sulfonylurea, which is why your full medicine list is reviewed.
• Worsening of existing diabetic retinopathy when blood sugar falls rapidly, reported with semaglutide in SUSTAIN-6.
• Loss of muscle alongside fat, which is why protein intake and resistance exercise are part of the plan rather than optional extras.

Both medicines slow stomach emptying, so anyone planning sedation, an endoscopy or an operation should tell the treating team they are on one of these medicines, because fasting instructions may need to change.

Who These Medicines Are Not For

• Anyone who is pregnant, breastfeeding, or planning a pregnancy in the near future.
• Anyone with a personal or family history of medullary thyroid carcinoma.
• Anyone with Multiple Endocrine Neoplasia type 2.
• Anyone with a history of pancreatitis.
• People with severe gastrointestinal disease, including delayed stomach emptying.
• People seeking cosmetic weight loss without a clinical indication.
• Anyone unwilling or unable to attend the review appointments that go with treatment.

That list is not exhaustive. Gallbladder disease, kidney problems, diabetic eye disease and a number of other medicines all need reviewing before a prescription is issued, and the only way to do that properly is a consultation.

What Affects the Cost in Sri Lanka

People often ask for a single price and are frustrated when they do not get one. The reason is not evasiveness. The cost of a supervised programme has three moving parts, and only one of them is the medicine itself.

An honest clinic will give you the current figure for your own prescription, the review schedule, and an estimate of what a realistic first three months would total, before you commit to anything. Be cautious of any offer that quotes a flat monthly price without knowing your dose, and be very cautious of any source offering these medicines without a prescription at all.

What Supervision Actually Involves

Supervision is not a formality to justify a fee. It is the difference between a treatment and a gamble. In practice it looks like this:

• An initial assessment covering medical history, current medicines, measurements and previous weight loss attempts.
• A decision about whether a prescription therapy is appropriate at all, and which one, with the reasoning explained to you.
• Each weekly dose given as a shot in clinic, so storage, handling and sharps disposal stay with us rather than with you.
• A first review around four weeks in, before any dose increase is considered.
• Further reviews at intervals of about four weeks while the dose is being stepped up, each increase conditional on the previous step being tolerated.
• Diet and activity guidance running alongside treatment the whole way through.
• A clear plan for stepping down or stopping, agreed before treatment starts.

It also means someone will tell you if it is not working. Reviewing progress honestly and stopping a treatment that is not delivering is part of good care, not a failure of it.

What Happens After You Stop

This is the part that gets least attention and deserves the most. Appetite returns once the medicine is stopped. The published extension of the STEP 1 trial reported that participants regained a large part of the weight they had lost in the year after stopping semaglutide, and the pattern is not unique to that medicine.

The practical conclusion is not that treatment is pointless. It is that the months on treatment are the window in which eating patterns, activity, sleep and habits have to change, because those are what carry the result afterwards. A programme that hands over the medicine and takes your money is setting you up for exactly that rebound.

Questions Worth Asking Any Clinic

• Who assesses me, and what is actually reviewed before a prescription is issued?
• Which medicine is being suggested for me, and on what clinical grounds?
• What is the full cost including reviews, and how will it change as my dose goes up?
• How often will I be seen, and what happens if side effects are bad between appointments?
• What is the plan for stopping, and what support continues afterwards?
• What would make you tell me this treatment is not working for me?

Next Step

If you want to understand whether either medicine is appropriate for you, the service pages set out how each programme runs at our Colombo clinic: tirzepatide (Mounjaro) weight management and semaglutide (Ozempic) weight management. If your concern is a stubborn fat pocket rather than overall body weight, fat freezing or liposuction is the more appropriate route.

Both medicines discussed here are prescription-only. Nothing on this page is medical advice, a recommendation to use a particular medicine, or an offer to supply one. Suitability can only be determined by a doctor at an individual consultation.